Hyderabad: Cipla Ltd will produce the primary three-in-one cocktail anti-AIDS medicine used for children. This accompanies the USFDA clearing a combining quantity of Boehringer Ingelheim’s Viramune, GlaxoSmithKline’s Epivir (or lamivudine) and Bristol-Myers Squibb’s Zerit (or stavudine), which are anti-retrovirals or drugs that fight back AIDS.

The commendation came under the US President’s Emergency Plan for AIDS Relief, or Pepfar, a $15 billion, 5-year plan to clash the threat in over 15 countries.

Cipla dipped 4.4% to Rs 192 after declaring a 30% fall in net earnings for the first quarter ended June 30, 2007.

The stock hit an intraday low of Rs 191.70 and an intraday high of Rs 199.85 during the day.

The scrip turned down on high volume of 21.1 lakh shares on the BSE counter.

The company recorded a 30% fall in its net profit to Rs 120 crore in Q1 June 2007 as against in the corresponding period (Q1 June 2006) of the last year.

Mumbai: Drug manufacturer Cipla posted a 29.73 percent enhancement in its net earnings at Rs 119.76 crore for the quarter ended June 30 as against Rs 170.43 crore for the same period of the last year.

The company’s total income (net of excise) augmented 4.34 per cent to Rs 920.37 crore for the June quarter against Rs 882.05 crore for the quarter ended June 30, 2006.

At the board meeting, the company’s directors also recommended a dividend of Rs 2 per equity share for the year 2006-2007 amounting to Rs 155.46 crore.

Shares of Cipla last traded at Rs 200.90, down 2.21 per cent on the BSE.